Vistagen Therapeutics (VTGN) Given a $6.00 Price Target by Maxim Group Analysts

Vistagen Therapeutics (NASDAQ:VTGN) received a $6.00 price objective from stock analysts at Maxim Group in a report issued on Wednesday, September 5th. The firm presently has a “buy” rating on the stock. Maxim Group’s target price indicates a potential upside of 331.65% from the company’s previous close.

Several other equities analysts have also recently weighed in on the stock. UBS Group started coverage on shares of Vistagen Therapeutics in a research report on Thursday, May 24th. They set an “outperform” rating and a $6.00 price objective on the stock. Oppenheimer set a $6.00 target price on shares of Vistagen Therapeutics and gave the company a “buy” rating in a research note on Friday, August 24th. Zacks Investment Research raised shares of Vistagen Therapeutics from a “hold” rating to a “buy” rating and set a $1.50 target price for the company in a research note on Thursday, August 30th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $22.00 price objective on shares of Vistagen Therapeutics in a research note on Friday, June 29th. Five equities research analysts have rated the stock with a buy rating, Vistagen Therapeutics has a consensus rating of “Buy” and a consensus target price of $8.30.

VTGN opened at $1.39 on Wednesday. The company has a market cap of $34.59 million, a PE ratio of -1.24 and a beta of 0.45. Vistagen Therapeutics has a twelve month low of $0.69 and a twelve month high of $2.65.

Vistagen Therapeutics (NASDAQ:VTGN) last posted its quarterly earnings data on Tuesday, August 14th. The company reported ($0.20) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.14) by ($0.06). sell-side analysts forecast that Vistagen Therapeutics will post -0.75 EPS for the current year.

Vistagen Therapeutics Company Profile

VistaGen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder.

Recommended Story: Return on Equity (ROE)

Receive News & Ratings for Vistagen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vistagen Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply